Abstract:Abstract Background Hepatocellular carcinoma (HCC) is one of the most common malignant cancers with poor prognosis and high incidence. The clinical data analysis of liver hepatocellular carcinoma samples downloaded from The Cancer Genome Atlas reveals that the THO Complex 1 (THOC1) is remarkable upregulated in HCC and associated with poor prognosis. However, the underlying mechanism remains to be elucidated. We hypothesize that THOC1 can promote the proliferation of HCC. The present study aims to identify THOC1 as the target for HCC treatment and broaden our sights into therapeutic strategy for this disease. Methods Quantitative RT - PCR, Western blot, immunofluorescence and immunohistochemistry were used to measure gene and protein expression. Colony formation and cell cycle analysis were performed to evaluate the proliferation. The gene set enrichment analysis were performed to identify the function which THOC1 was involved in. The effects of THOC1 on the malignant phenotypes of hepatocellular cells were examined in vitro and in vivo. Results The gene set enrichment analysis reveals that THOC1 can promote the proliferation and G2/M cell cycle transition of HCC. Similarly, experimental results demonstrate that THOC1 promotes HCC cell proliferation and cell cycle progression. The knockdown of THOC1 leads to R-loop formation and DNA damage and confers sensitivity to cisplatin. In addition, in vivo data demonstrate that THOC1 can enhance tumorigenesis by increasing tumor cell proliferation. Furthermore, virtual screening predicts that THOC1 as a direct target of luteolin. Luteolin can induce DNA damage and suppress the proliferation of HCC by targeting THOC1. Furthermore, the inhibition of THOC1 activity by luteolin enhances the chemosensitivity of HCC tumor cells to cisplatin. Conclusions THOC1 was identified as a predictive biomarker vital for HCC-targeted treatments and improvement of clinical prognosis. Luteolin combined with cisplatin can effectively suppress HCC tumor growth, indicating a potential and effective therapeutic strategy that uses luteolin in combination with conventional cytotoxic agents for HCC treatment.

Kctd11 Inhibits Growth and Metastasis of Hepatocellular Carcinoma Through Activating Hippo Signaling

Targeting KCTD1 As a Potential Novel Therapy Ameliorates Hepatocellular Carcinoma Progression Via the HIF-1α/VEGF Pathway

Metallothionein 1H (MT1H) Functions As a Tumor Suppressor in Hepatocellular Carcinoma Through Regulating Wnt/β-catenin Signaling Pathway

Silencing of KNTC1 Inhibits Hepatocellular Carcinoma Cells Progression Via Suppressing PI3K/Akt Pathway

BCL11B Suppresses Tumor Progression and Stem Cell Traits in Hepatocellular Carcinoma by Restoring P53 Signaling Activity

Hippocalcin‐like 1 Suppresses Hepatocellular Carcinoma Progression by Promoting P21waf/cip1 Stabilization by Activating the ERK1/2‐MAPK Pathway

PCDH10 Gene Inhibits Cell Proliferation and Induces Cell Apoptosis by Inhibiting the PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma Cells

KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway

Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma

CNDP1 Suppresses the Malignant Behavior of Hepatoma Cell via Restricting PI3K-AKT-mTOR Activation

KIF2C: a Novel Link Between Wnt/β-catenin and Mtorc1 Signaling in the Pathogenesis of Hepatocellular Carcinoma

HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness

KCTD12 Promotes G1/S Transition of Breast Cancer Cell Through Activating the AKT/FOXO1 Signaling

Expression And Function Analysis Of Mitotic Checkpoint Genes Identifies Ttk As A Potential Therapeutic Target For Human Hepatocellular Carcinoma

KIFC1, a Novel Potential Prognostic Factor and Therapeutic Target in Hepatocellular Carcinoma.

Proline-rich Protein 11 Silencing Inhibits Hepatocellular Carcinoma Growth and Epithelial-Mesenchymal Transition Through Β-Catenin Signaling.

KCTD9 inhibits the Wnt/β-catenin pathway by decreasing the level of β-catenin in colorectal cancer

PCDH20 functions as a tumour-suppressor gene through antagonizing the Wnt/β-catenin signalling pathway in hepatocellular carcinoma.

High Expression of Hexokinase Domain Containing 1 is Associated with Poor Prognosis and Aggressive Phenotype in Hepatocarcinoma.

Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin

ARHGEF11 Promotes Proliferation and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Through Activation of &Amp;#x3b2;-Catenin Pathway